Pliant Therapeutics Inc (PLRX) 股票價格預測

Pliant Therapeutics, Inc. engages in the discovery, development and commercialization of therapies for fibrotic diseases. The company is headquartered in South San Francisco, California and currently employs 49 full-time employees. The company went IPO on 2020-06-03. The Company’s lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of avb6 and avb1 integrins that is in development in the lead indication for the treatment of idiopathic pulmonary fibrosis, or idiopathic pulmonary fibrosis (IPF). The Company’s second clinical program, PLN-101095, is a small molecule, dual selective inhibitor of integrins avb8 and avb1 for the treatment of solid tumors that are resistant to immune checkpoint inhibitors. Its Phase 1-ready program PLN-101325, is in development for treatment of muscular dystrophies, including Duchenne muscular dystrophy. PLN-101325 is a monoclonal antibody designed to act as an allosteric agonist of integrin a7b1.